A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients


    loading  Checking for direct PDF access through Ovid

Abstract

Pharmacokinetics of vancomycin and dosage requirements were evaluated prospectively in 28 pediatric cancer patients 9 months to 13 years of age. The predictive performance of a two-compartment Bayesian forecasting program was also evaluated. A mean (±SD) daily dosage of 75 ± 22 mg/kg/day was necessary to attain a mean peak serum vancomycin concentration (SVC) of 23.1 ± 5.8 mg/liter and a mean trough SVC of 6.2 ± 2.3 mg/liter. Mean vancomycin clearance, volume of distribution and serum half-life were 0.153 ± 0.033 liter/hour/kg, 0.63 ± 0.08 liter/kg and 2.95 ± 0.48 hours. Final peak SVCs, which reflected the last dosage regimens received, were predicted with minimal bias (mean prediction error, −1.2 mg/liter) and accurate precision (root mean-squared prediction error, 2.0 mg/liter) whereas trough SVCs were predicted with even smaller bias (mean prediction error, −0.1 mg/liter) and greater precision (root mean-squared prediction error, 0.8 mg/liter). This study showed that pediatric cancer patients with normal renal function required vancomycin dosage regimens substantially greater than the standard 40 mg/kg/day to attain the desired SVCs.

    loading  Loading Related Articles